Cargando…
A Novel Peptide Ameliorates LPS-Induced Intestinal Inflammation and Mucosal Barrier Damage via Its Antioxidant and Antiendotoxin Effects
Intestinal inflammation is an inflammatory disease resulting from immune dysregulation in the gut. It can increase the risk of enteric cancer, which is a common malignancy globally. As a new class of anti-inflammatory agents, native peptides have potential for use in the treatment of several intesti...
Autores principales: | Zhang, Lulu, Wei, Xubiao, Zhang, Rijun, Si, Dayong, Petitte, James N., Ahmad, Baseer, Zhang, Manyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720008/ https://www.ncbi.nlm.nih.gov/pubmed/31443263 http://dx.doi.org/10.3390/ijms20163974 |
Ejemplares similares
-
A Novel Cecropin-LL37 Hybrid Peptide Protects Mice Against EHEC Infection-Mediated Changes in Gut Microbiota, Intestinal Inflammation, and Impairment of Mucosal Barrier Functions
por: Wei, Xubiao, et al.
Publicado: (2020) -
Expression and Purification of Hybrid LL-37Tα1 Peptide in Pichia pastoris and Evaluation of Its Immunomodulatory and Anti-inflammatory Activities by LPS Neutralization
por: Ahmad, Baseer, et al.
Publicado: (2019) -
Targeting the TLR2 Receptor With a Novel Thymopentin-Derived Peptide Modulates Immune Responses
por: Wei, Xubiao, et al.
Publicado: (2021) -
C-Terminal Amination of a Cationic Anti-Inflammatory Peptide Improves Bioavailability and Inhibitory Activity Against LPS-Induced Inflammation
por: Zhang, Lulu, et al.
Publicado: (2021) -
Design and Development of a Novel Peptide for Treating Intestinal Inflammation
por: Zhang, Lulu, et al.
Publicado: (2019)